Microglial activation contributes to cognitive impairments in rotenone-induced mouse Parkinson's disease model

Dongdong Zhang1, Sheng Li2, Liyan Hou1,2

  • 1School of Public Health, Dalian Medical University, Dalian, 116044, China.

Abstract

Insights

Microglial activation drives cognitive decline in Parkinson's disease (PD). Inhibiting microglia improves cognitive function and reduces neuroinflammation and neuronal damage in a mouse model of PD.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Cognitive decline is a common and debilitating symptom in Parkinson's disease (PD).
  • The underlying mechanisms of cognitive impairment in PD are not fully understood.
  • Overactivated microglia and subsequent neuroinflammation are implicated in various neurological disorders, including PD.

Purpose of the Study:

  • To investigate the role of microglia in cognitive deficits observed in a rotenone-induced mouse model of Parkinson's disease.
  • To explore the therapeutic potential of targeting microglia for cognitive improvement in PD.

Main Methods:

  • Utilized a rotenone-induced mouse model to mimic Parkinson's disease pathology.
  • Administered PLX3397 (microglial inhibitor) and minocycline (antibiotic) to deplete or inactivate microglia.
  • Assessed cognitive performance using behavioral tests (Morris water maze, objective recognition, passive avoidance).
  • Quantified neurodegeneration, synaptic loss, alpha-synuclein phosphorylation, glial activation, apoptosis, inflammatory gene expression, and lipid peroxidation.

Main Results:

  • Rotenone administration induced dose-dependent cognitive deficits, neurodegeneration, synaptic loss, and microglial activation in mice.
  • Microglial activation was observed to precede neurodegeneration.
  • Depletion or inactivation of microglia significantly ameliorated cognitive deficits, reduced neuronal damage, and attenuated alpha-synuclein pathology.
  • Targeting microglia reduced neuroinflammation, oxidative stress, and neuronal apoptosis.

Conclusions:

  • Microglial activation plays a critical role in mediating cognitive impairments in Parkinson's disease.
  • Neuroinflammation, oxidative stress, and apoptosis driven by microglia contribute to PD-related cognitive deficits.
  • Targeting microglial activation presents a potential therapeutic strategy for managing cognitive dysfunction in Parkinson's disease.